Positron-emission tomography with 18F-fluorodeoxyglucose in a patient with acromegaly

Authors:

Abstract
Acromegaly is a rare neuroendocrine disorder caused by autonomous hyperproduction of growth hormone, most commonly due to a pituitary adenoma, which accounts for more than 95% of cases. Magnetic resonance imaging (MRI) is the standard imaging modality for this condition; however, it cannot be performed in some patients, for example due to the presence of MRIincompatible metallic implants, which creates diagnostic challenges in determining indications for surgical treatment. We report the case of a 59-year-old patient with biochemically confirmed acromegaly in whom MRI was contraindicated because of an iron-containing metallic fixation device in the clavicular region placed after a fracture. Contrast-enhanced computed tomography (CT) revealed pituitary enlargement but did not provide sufficient diagnostic accuracy. For lesion localization, positron emission tomography combined with computed tomography (PET/CT) using 18 F-fluorodeoxyglucose (18F-FDG) was performed and demonstrated a focus of increased radiotracer uptake in the sellar region. Based on these findings, the patient underwent transsphenoidal adenomectomy. The diagnosis of somatotropinoma was confirmed by immunohistochemistry, with growth hormone expression detected in 100% of tumor cells. Following surgery, the patient achieved remission of acromegaly. This case suggests that 18 F-FDG PET/CT may serve as an alternative modality for lesion localization in acromegaly when MRI is not feasible or is contraindicated. The diagnostic performance and clinical role of this method require further investigation.

This publication has 15 references indexed in Scilit: